IRLAB Therapeutics: IRLAB Announces Top-Line Results from Phase IIb Trial of Mesdopetam in Parkinson's disease
GOTHENBURG, SE / ACCESSWIRE / January 17, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) a company discovering and developing novel treatments for Parkinson's disease, today announced the top-line results
Source: finanznachrichten.de